Kolexia
Del Piano Francesco Gynécologie
Del Piano Francesco
Gynécologie
Hopitaux Du Leman
Thonon-les-Bains, France
41 Activités
207 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du sein Tumeurs de l'ovaire Carcinome épithélial de l'ovaire Tumeurs du sein triple-négatives Micrométastase tumorale Effets secondaires indésirables des médicaments Métastase tumorale Récidive tumorale locale Prolapsus d'organe pelvien

Collaborateurs

Voir plus
You Benoit
You Benoit
Hôpital Lyon Sud, Pierre-Bénite, France
Dalenc Florence
Dalenc Florence
Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France
Bachelot Thomas
Bachelot Thomas
Centre Léon-Bérard, Lyon, France
Venat Laurence
Venat Laurence
Hôpital Dupuytren, Limoges, France

Industries

Voir plus
Novartis
7 collaboration(s)
Dernière en 2023
B3TSI
4 collaboration(s)
Dernière en 2023
Lilly
2 collaboration(s)
Dernière en 2023
Daiichi Sankyo
2 collaboration(s)
Dernière en 2022

Dernières activités

Voir plus
Axillary Node Dissection Versus no Dissection in Breast Cancer With Positive Sentinel Lymph Node: A Non Inferiority Randomized Multicenter Phase III Trial of Axillary Node Dissection Versus no Axillary Node Dissection in Case of Positive Sentinel Lymph Node in Invasive Breast Cancer
Essai Clinique (Centre Paoli-Calmettes)   09 janvier 2024
RIBOLARIS: Neoadjuvant and Adjuvant Ribociclib and Endocrine Therapy for Clinically High-risk Estrogen Receptor-positive (ER+) and HER2-negative (HER2-) Breast Cancer
Essai Clinique (Novartis)   06 octobre 2023
793P Strong relationships between the CA-125 KELIM score and the tumor biological effects after neo-adjuvant chemotherapy in advanced ovarian cancer patients: CHIVA trial (GINECO)
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
CHIVA: Randomized Double Blind Placebo-controlled Phase II Trial of Vargatef® (Nintedanib) in Addition to First Line Chemotherapy With Interval Debulking Surgery in Patients With Adenocarcinoma of the Ovary, the Fallopian Tube or Serous Adenocarcinoma of the Peritoneum
Essai Clinique (ARCAGY/ GINECO GROUP)   05 septembre 2023
TAPAZ: A Randomized Phase II Study of Pazopanib and Weekly Paclitaxel in Patients With Platinum Resistant/Refractory Ovarian Cancer Who Relapse During Bevacizumab Maintenance
Essai Clinique (Novartis)   05 septembre 2023
Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving at Least One Year of Adjuvant Hormone Therapy: Randomized, Double Blind, Multicentric Phase III Trial Evaluating the Safety and Benefit of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer Who Remain Free of Disease After Receiving at Least 1 Year of Adjuvant Hormone Therapy
Essai Clinique (Unicancer)   28 février 2023
Neoadjuvant chemotherapy with or without nintedanib for advanced epithelial ovarian cancer: Lessons from the GINECO double-blind randomized phase II CHIVA trial.
Gynecologic oncology   25 janvier 2023
CHEOPS trial: a GINECO group randomized phase II assessing addition of a non-steroidal aromatase inhibitor to oral vinorelbine in pre-treated metastatic breast cancer patients.
Breast cancer (Tokyo, Japan)   05 janvier 2023
Paclitaxel with or without pazopanib for ovarian cancer relapsing during bevacizumab maintenance therapy: The GINECO randomized phase II TAPAZ study.
Gynecologic oncology   26 juillet 2022
Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology   23 mai 2022